Abera Bioscience ABNGM: ABERA

ABERA: Secured funding and positive R&D milestones drive clinical progress despite ongoing losses

· Issued by Abera Bioscience AB

Strong progress in vaccine R&D, with secured financing and grants supporting clinical advancement of pneumococcal and influenza candidates. Q3 saw higher grant income but continued net losses, with a robust cash position and equity base.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Abera Bioscience AB on 6ix

Earlier from Abera Bioscience

Later from Abera Bioscience

All Abera Bioscience news releases